Functional clinical outcomes in multiple sclerosis: Current status and future prospects

Rana Karabudak 1, Maurice Dahdaleh 2, Mohammed Aljumah 3, Raed Alroughani 4, I Ahmed Alsharoqi 5, Abdulrahman M AlTahan 6, Saeed A Bohlega 7, Abdulkader Daif 6, Dirk Deleu 8, Amer Amous 9, Jihad S Inshasi 10, Peter Rieckmann 11, Mohammed A Sahraian 12, Bassem I Yamout 13

Affiliations

01 May 2015

-

doi: 10.1016/j.msard.2015.03.004

Abstract

For decades, the Expanded Disability Status Scale (EDSS) has been the principal measure of disability in clinical trials in patients with multiple sclerosis (MS) and in clinical practice. However, this test is dominated by effects on ambulation. Composite endpoints may provide a more sensitive measure of MS-related disability through the measurement of additional neurological functions. The MS Functional Composite (MSFC) includes a walking test (25-ft walk) plus tests of upper extremity dexterity (9-hole peg test) and cognitive function (Paced Auditory serial Addition test [PASAT]). Replacing PASAT with the Symbol Digit Modality test, a more sensitive test preferred by patients, may improve the clinical utility of the MSFC. In addition, disease-specific measures of QoL may be used alongside the MSFC (which does not include measurement of QoL). Clinical data suggest that disease-modifying therapies may delay or prevent relapse, and better composite measures will be valuable in the assessment of disease activity-free status in people with MS.

Keywords: Clinical outcome measures; Clinical trials; Disease-modifying therapies; Multiple sclerosis.

Similar articles

Binocular low-contrast letter acuity and the symbol digit modalities test improve the ability of the Multiple Sclerosis Functional Composite to predict disease in pediatric multiple sclerosis.

Waldman AT, Chahin S, Lavery AM, Liu G, Banwell BL, Liu GT, Balcer LJ.Mult Scler Relat Disord. 2016 Nov;10:73-78. doi: 10.1016/j.msard.2016.08.012. Epub 2016 Aug 26.PMID: 27919503 Free PMC article.

Clinical outcome measures for research in multiple sclerosis.

Balcer LJ.J Neuroophthalmol. 2001 Dec;21(4):296-301. doi: 10.1097/00041327-200112000-00014.PMID: 11756863 Review.

Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test.

Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH.Mult Scler. 2010 Feb;16(2):228-37. doi: 10.1177/1352458509354552. Epub 2009 Dec 22.PMID: 20028710

The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials.

Rudick RA, Cutter G, Reingold S.Mult Scler. 2002 Oct;8(5):359-65. doi: 10.1191/1352458502ms845oa.PMID: 12356200 Review.

Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.

Ozakbas S, Cagiran I, Ormeci B, Idiman E.J Neurol Sci. 2004 Mar 15;218(1-2):3-7. doi: 10.1016/j.jns.2003.09.015.PMID: 14759626

Cited by

The role of machine learning in developing non-magnetic resonance imaging based biomarkers for multiple sclerosis: a systematic review.

Hossain MZ, Daskalaki E, Brüstle A, Desborough J, Lueck CJ, Suominen H.BMC Med Inform Decis Mak. 2022 Sep 15;22(1):242. doi: 10.1186/s12911-022-01985-5.PMID: 36109726 Free PMC article.

Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.

Lehnert T, Röver C, Köpke S, Rio J, Chard D, Fittipaldo AV, Friede T, Heesen C, Rahn AC.Syst Rev. 2022 Jul 1;11(1):134. doi: 10.1186/s13643-022-01997-2.PMID: 35778721 Free PMC article.

The Role of Transcranial Magnetic Stimulation as a Surrogate Marker of Disease Activity in Patients with Multiple Sclerosis: A Literature Review.

Alsharidah MM, Uzair M, Alseneidi SS, Alkharan AA, Bunyan RF, Bashir S.Innov Clin Neurosci. 2022 Jan-Mar;19(1-3):8-14.PMID: 35382066 Free PMC article. Review.

Outcome measures assisting treatment optimization in multiple sclerosis.

Pardo G, Coates S, Okuda DT.J Neurol. 2022 Mar;269(3):1282-1297. doi: 10.1007/s00415-021-10674-8. Epub 2021 Aug 2.PMID: 34338857 Free PMC article. Review.

Cognitive impairment in multiple sclerosis: diagnosis and monitoring.

Meca-Lallana V, Gascón-Giménez F, Ginestal-López RC, Higueras Y, Téllez-Lara N, Carreres-Polo J, Eichau-Madueño S, Romero-Imbroda J, Vidal-Jordana Á, Pérez-Miralles F.Neurol Sci. 2021 Dec;42(12):5183-5193. doi: 10.1007/s10072-021-05165-7. Epub 2021 Apr 1.PMID: 33796947 Free PMC article. Review.

References

https://pubmed.ncbi.nlm.nih.gov/

Page Navigation